Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
Executive Summary
FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.
You may also be interested in...
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
The Contrave "complete response" letter could mean research in the category is sidelined now that all three of the current obesity drug candidates have been rejected.
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
Orexigen Therapeutics has a big decision on its hands – how to proceed with its Contrave program – now that FDA wants to see a large cardiovascular outcomes study before the drug can be considered for approval.
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
Orexigen Therapeutics has a big decision on its hands – how to proceed with its Contrave program – now that FDA wants to see a large cardiovascular outcomes study before the drug can be considered for approval.